Why hip cartilage cannot repair itself

Hip cartilage cannot repair itself because it has no blood supply. Articular cartilage — the smooth hyaline tissue lining the femoral head and acetabulum — is avascular, aneural, and alymphatic. Without blood vessels, there is no route for the progenitor cells, nutrients, and inflammatory signals that drive healing elsewhere in the body to reach a damaged area. A scratch on skin closes within days; a focal cartilage defect in the hip joint does not close at all.

Left alone, focal hip chondral defects tend to progress rather than stabilise. Exposed subchondral bone becomes a source of pain, and the surrounding cartilage faces increasing mechanical stress, accelerating the cycle of wear. This is why both ChondroFiller injection and surgical cartilage repair exist: each pathway substitutes for the biology the tissue cannot generate on its own, one through an outpatient injectable collagen scaffold, the other through an operating-theatre procedure — different mechanisms, different care settings, a shared aim of protecting the hip joint and reducing the risk of early joint replacement.

How ChondroFiller injection works in the hip joint

Unlike surgical cartilage repair, the ChondroFiller injection pathway requires no operating theatre, no incision, and no general anaesthetic. The procedure is carried out as an outpatient appointment, with the collagen gel delivered under real-time ultrasound guidance directly into the focal hip joint defect.

The material itself is an acellular, murine-derived Type I collagen scaffold — a CE-marked Class III medical device that gels in situ within approximately 3–5 minutes of placement. Once stable, it acts as a three-dimensional matrix that draws the patient's own progenitor cells inward from surrounding synovium and subchondral bone. Over roughly 3–6 months, those recruited cells progressively remodel the scaffold into fibrocartilage-like repair tissue. This process is termed matrix-induced chondrogenesis, and it is what distinguishes ChondroFiller injection from other intra-articular treatments.

Viscosupplementation (hyaluronic acid) works by lubricating the joint surface; it does not provide a structural matrix or aim for tissue regeneration. Hydrogel fillers such as Arthrosamid function as non-degradable mechanical cushions — they occupy space and redistribute load but do not recruit cells or remodel. ChondroFiller injection is neither: it is a regenerative scaffold, not a lubricant or a filler.

In hip-specific clinical data, patients treated with ChondroFiller injection have shown a mean improvement in the modified Harris Hip Score of approximately 30 points. Because the entire process is image-guided and outpatient, rehabilitation demands are substantially lower than for any surgical alternative.

Hip cartilage surgery: what the options involve

Surgical cartilage repair in the hip encompasses several distinct techniques, each with its own defect-size threshold, staging requirements, and demands on the patient — and it is worth being precise about what each actually involves before comparing any of them to a non-surgical pathway.

Microfracture has historically been the first-line surgical option for small focal hip chondral lesions (typically under 2–4 cm²). Performed arthroscopically under general or spinal anaesthesia, it involves perforating the subchondral bone to release marrow cells into the defect. The tissue that forms, however, is fibrocartilage — mechanically inferior to native hyaline tissue — and published evidence shows clinical benefit frequently declining beyond two to three years, with reoperation rates reaching up to 41%. Its use is now declining as more regenerative options have become available.

AMIC (autologous matrix-induced chondrogenesis) adds a collagen membrane over the microfracture bed in the same operative session, providing a scaffold for the released marrow cells. This single-stage enhancement aims for better tissue quality than microfracture alone, bridging the gap towards more structured repair without the additional staging that cell-based techniques require.

ACI and MACI (autologous chondrocyte implantation / matrix-induced ACI) are indicated for larger isolated defects, typically above 2–4 cm², where genuine structural reconstruction is the aim. Both are two-stage procedures: a biopsy harvests chondrocytes in the first operation; those cells are cultured and then reimplanted — either under a periosteal patch (ACI) or on a collagen membrane (MACI) — in a second. Published data show IKDC improvement of around 30–35 points, comparable to ChondroFiller injection, but complication rates reach up to 17% and reoperation rates up to 37%, alongside the logistical burden of two separate procedures.

OATS and mosaicplasty transfer intact osteochondral plugs from a lower-load donor area of the hip or knee to the defect site — well suited to lesions of roughly 1–2 cm² (up to 4 cm² in mosaic configurations). The technique is single-stage but carries a meaningful consideration: donor-site morbidity, where a secondary defect is created to fill the primary one.

All of these options require operating-theatre conditions — debridement to a clean bone bed, a dry joint environment, and anaesthesia — placing them at a higher acuity level than an outpatient injection pathway from the outset.

Patients who suit ChondroFiller injection

The focal-defect candidate

The patient most suited to ChondroFiller injection in its regenerative role typically presents with a well-defined, full-thickness Grade III/IV cartilage defect up to 6 cm², bordered by healthy tissue on all sides. The surrounding cartilage and subchondral bone must be intact enough to anchor the collagen scaffold as it remodels — without that foundation, cell recruitment is unlikely to succeed. Joint alignment and stability matter equally: a hip that loads asymmetrically will disrupt scaffold integration before any repair tissue can form.

Symptom duration is a practical filter. Shorter pre-operative symptom duration correlates with better scaffold fill rates and outcomes, making earlier referral — before cumulative changes widen the defect or compromise surrounding tissue — generally the better course.

A common clinical example is the younger, active patient with cam-type femoroacetabular impingement (FAI). Cam morphology tends to produce anterosuperior acetabular lesions that are focal, well-demarcated, and often substantial in patients under 40 — precisely the profile for which a single image-guided injection visit offers a genuine cartilage-preserving alternative to microfracture.

This pathway also suits patients who are medically unsuited to anaesthesia or cannot commit to the staged rehabilitation that hip arthroscopy requires. For this group the decision is not a compromise on treatment intent but a reflection of clinical priorities.

The advanced osteoarthritis candidate

For a second group — those with Kellgren-Lawrence Grade III/IV hip osteoarthritis, or a Tönnis grade approaching the threshold for joint replacement — ChondroFiller injection serves a distinct and more limited role. The aim here is not focal tissue regeneration but additive cushioning: the collagen matrix is placed across broadly worn articular surfaces to provide a viscoelastic buffer, helping to manage pain and extend function while joint replacement remains premature or is something the patient wishes to defer.

Patients and clinicians should be clear that this represents a different treatment aim from the regenerative pathway. The scaffold is not rebuilding a localised defect; it is supplementing a degraded surface — a useful bridge, but not a substitute for joint replacement when that stage arrives.

Patients who suit surgical hip cartilage repair

The pivot from injectable scaffold to surgical repair is driven by what the hip joint itself can and cannot support.

When a defect exceeds the reliable fill capacity of an injectable collagen scaffold — because it is too large, too structurally deep, or situated in a joint with compromised surrounding borders — the preconditions for acellular matrix-induced chondrogenesis are absent. Without a viable perimeter to anchor the scaffold and intact subchondral bone to supply migrating progenitor cells, integration will not occur. These patients require a subtractive, operating-theatre approach: debridement to a clean bone bed, then a technique matched to defect size and the patient's wider hip joint health.

The exclusion criteria for ChondroFiller injection map directly onto the surgical indications. Tönnis Grade 2–3 generalised hip osteoarthritis, inflammatory joint disease such as rheumatoid or psoriatic arthritis, active infection, or a defect so extensive that scaffold integration is unreliable — each redirects the decision toward surgical assessment. The ideal surgical candidate presents with a single, well-demarcated focal defect, healthy surrounding cartilage, no widespread joint degeneration, and a stable, well-aligned hip.

For younger patients whose long-term priority is hyaline-like structural reconstruction and whose hip biology can sustain a two-stage process, ACI or MACI carries the strongest published structural evidence — at the cost of a higher procedural burden, as set out in the previous section. Where the defect is focal but smaller and the joint is otherwise sound, single-stage options such as AMIC or OATS may be more appropriate.

One group lies beyond cartilage repair by either route. Diffuse, advanced degeneration — widespread surface loss, multi-point bone contact — is the domain of hip replacement, not preservation. Being direct about this distinction protects patients from pursuing a pathway that cannot deliver durable benefit at their stage of joint disease.

What the evidence shows — and where gaps remain

Evidence for ChondroFiller injection in the hip is credible but still maturing. Most of the comparative data — IKDC improvement figures, complication rates, reoperation rates — derives from knee cohorts; hip-specific series are smaller and shorter in follow-up, and no long-term randomised controlled trial has yet compared ChondroFiller injection directly to ACI, MACI, or microfracture specifically in the hip joint. That gap is worth naming plainly.

Published hip-specific cohorts report a modified Harris Hip Score (mHHS) improvement of approximately 30 points following ChondroFiller injection — directionally consistent with knee outcomes and a clinically meaningful functional gain, though not yet confirmed by extended hip follow-up data.

The procedural risk comparison with surgical repair is nonetheless instructive on the available evidence. ACI and MACI produce broadly similar functional improvements — IKDC gains of approximately 30–35 points in published cohort data — but carry complication rates reaching up to 17% and reoperation rates up to 37%. For ChondroFiller injection, published cohort data indicate a complication rate of approximately 0% and reoperation rates of 3–8%. Those are meaningful differences in risk profile, even acknowledging that the underlying patient populations are not identical across studies.

For patients across Lincolnshire and the wider non-London catchment, Lincolnshire Hip accepts assessment without GP referral, combining imaging and clinical evaluation to determine which pathway the individual hip joint can actually support.

On current evidence, for patients with a focal defect, a stable and well-aligned hip, and a preference to avoid theatre, the injection route appears to offer comparable functional gains at substantially lower procedural burden. Where structural reconstruction takes priority — larger defects, younger patients prioritising hyaline-like tissue, staged surgery that is acceptable to the patient — surgical repair carries the stronger structural evidence base. Hip-specific long-term trials would sharpen both conclusions; that evidence gap is a feature of a developing field, not a reason to discount what the short-term data consistently shows.